Peculiarities of differential diagnostics of inflammatory and noninflammatory myelopathies
https://doi.org/10.21886/2712-8156-2025-6-2-118-128
Abstract
Despite the heterogeneous etiology of myelopathies and the stereotyping of the main clinical manifestations of spinal cord lesions, pathognomonic clinical features, signs of involvement of extraspinal structures, features of the course of the pathological process, differences in the presentation of lesions on sagittal and axial magnetic resonance images and laboratory diagnostic data allow differential diagnosis between both inflammatory and non-inflammatory forms, and within these groups themselves.
About the Authors
Yu. N. Sorokin
FSBEI of HE “Rostov State Medical University” of the Ministry of Health of Russia
Russian Federation
Russian Federation
Yuri N. Sorokin
Rostov-on-Don
E. Yu. Sorokina
FSBEI of HE “Rostov State Medical University” of the Ministry of Health of Russia
Russian Federation
Russian Federation
Elena Yu. Sorokina
Rostov-on-Don
References
1. Sechi E., Flanagan E.P. Evaluation and Management of Acute Myelopathy. Semin. Neurol. 2021; 41(05):511-529. https://doi.org/10.1055/s-0041-1733792
2. Pardo C.A. Clinical Approach to Myelopathy Diagnosis. Continuum (Minneap Minn). 2024;30(1):14-52. https://doi.org/10.1212/CON.0000000000001390
3. Valencia-Sanchez К., Flanagan E.P. Uncommon inflammatory/immunerelated myelopathies. J. of Neuroimmunology. 2021;361:577750. https://doi.org/10.1016/j.jneuroim.2021.577750
4. Jarius S., Aktas O., Ayzenberg I., Bellmann-Strobl J., Berthele A., Giglhuber K. et al. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J. Neurol. 2023;270:3341-3368. https://doi.org/10.1007/s00415-023-11634-0
5. Yevtushenko S.K., Skoromets А.А., Skoromets А.Р., Yevtushenko О.S. Selected Lectures on Pediatric and General Neurology. Мoscow: Meditsinskoe informatsionnoe agentstvo; 2021. (In Russ.)
6. Cacciaguerra L., Flanagan E.P. Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders. Neurologic Clinics. 2024;42(1):77-114. https://doi.org/10.1016/j.ncl.2023.06.009
7. Passeri M., Matthews E., Kammeyer R., Piquet A.L. Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing. Front. Neurol. 2022;13:972143. https://doi.org/10.3389/fneur.2022.972143
8. Skoromets A.A., Afanasyev V.V., Skoromets A.P., Skoromets T.A. Vascular diseases of the spinal cord. St. Petersburg: Polytechnics; 2019. (In Russ.)
9. Zalewski N.L., Rabinstein A.A., Krecke K.N., Brown R.D.Jr., Wijdicks E.F.M., Weinshenker B.G. et al. Characteristics of Spontaneous Spinal Cord Infarction and Proposed Diagnostic Criteria. JAMA Neurol. 2019;76(1):56-63. https://doi.org/10.1001/jamaneurol.2018.2734
10. Murphy O.C., Barreras P., Villabona-Rueda A., Mealy M., Pardo C.A. Identification of specific causes of myelopathy in a large cohort of patients initially diagnosed with transverse myelitis. J. of the Neurological Sciences. 2022;442:120425. https://doi.org/10.1016/j.jns.2022.120425
11. Cacciaguerra L., Sechi E., Rocca M.A., Filippi M., Pittock S.J., Flanagan E.P. Neuroimaging features in inflammatory myelopathies: A review. Front. Neurol. 2022;13:993645. https://doi.org/10.3389/fneur.2022.993645
12. Barreras P., Fitzgerald K.C., Mealy M.A., Jimenez J.A., Becker D., Newsome S.D. et al. Clinical biomarkers differentiate myelitis from vascular and other causes of myelopathy. Neurology. 2018;90:e12-21. https://doi.org/10.1212/WNL.0000000000004765
13. Levy M. Immune-Mediated Myelopathies. Continuum (Minneap Minn). 2024;30(1):180-198. https://doi.org/10.1212/CON.0000000000001382
14. Lopez Chiriboga S., Flanagan E.P. Myelitis and other autoimmune myelopathies. Continuum (Minneap Minn). 2021;27(1):62-92. https://doi.org/10.1212/CON.0000000000000900
15. Pfausler B., Rass V., Lindner A. Infektionen des Rückenmarks und der angrenzenden Strukturen [Infections of the spinal cord and adjacent structures]. Nervenarzt. 2023;94(4):287-295. (In German). https://doi.org/10.1007/s00115-023-01439-x
16. Fletcher A.M., Bhattacharyya S. Infectious Myelopathies. Continuum (Minneap Minn). 2024;30(1):133-159. https://doi.org/10.1212/CON.0000000000001393
17. Marignier R. Acute and subacute myelopathy. Revue Neurologique. 2021;177(5):557-566. https://doi.org/10.1016/j.neurol.2020.08.003
18. Fadda G., Flanagan E.P., Cacciaguerra L., Jitprapaikulsan J., Solla P., Zara P., Sechi E. Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD. Front. Neurol. 2022;13:1011579. https://doi.org/10.3389/fneur.2022.1011579
19. Ponomarev G.V., Skoromets A.A., Krasnov V.S., Rodionova O.V., Glistenkova D.D., Porkhun N.F., et al. Vascular myelopathy: causes and mechanisms, possibilities of diagnosis and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(1):12-16. (In Russ.) https://doi.org/10.14412/2074-2711-2018-1-12-16
20. Murphy O.C., Salazar-Camelo A., Jimenez J.A., Barreras P., Reyes M.I., Garcia M.A. et al. Clinical and MRI phenotypes of sarcoidosis-associated myelopathy. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e722. https://doi.org/10.1212/NXI.0000000000000722
21. Fink J.K. Hereditary Myelopathies. Continuum (Minneap Minn). 2021;27(1):185-204. https://doi.org/10.1212/con.0000000000000934
22. Kranz P.G., Amrhein T.J. Imaging approach to myelopathy: acute, subacute, and chronic. Radiol. Clin. North. Am. 2019;57:257-279. https://doi.org/10.1016/j.rcl.2018.09.006
23. Sechi E., Morris P.P., McKeon A., Pittock S.J., Hinson S.R., Weinshenker B.G. et al. Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis. J. Neurol. Neurosurg. Psychiatry. 2019;90:488-490. https://doi.org/10.1136/jnnp-2018-318004
24. Banwell B., Bennett J.L., Marignier R., Kim H.Jin., Brilot F., Flanagan E.P. et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet. Neurol. 2023:22(3);268-282. https://doi.org/10.1016/S1474-4422(22)00431-8
25. Saballegue J.D., Tiongson M.P. Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease. Cureus 2024;16(5):e60004. https://doi.org/10.7759/cureus.60004
26. Zara P., Dinoto A., Carta S., Floris V., Turilli D., Budhram A. et al. Non-demyelinating disorders mimicking and misdiagnosed as NMOSD: a literature review. Eur. J. Neurol. 2023;30:3367-3376. https://doi.org/10.1111/ene.15983
Review
For citations:
Sorokin Yu.N., Sorokina E.Yu. Peculiarities of differential diagnostics of inflammatory and noninflammatory myelopathies. South Russian Journal of Therapeutic Practice. 2025;6(2):118-128. (In Russ.) https://doi.org/10.21886/2712-8156-2025-6-2-118-128
Views:
35
Email this article 